TMCnet

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...
Seeking Alpha

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Greetings, and welcome to PDS Bio Clinical Programs Update Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
Business Insider

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...
BizTimes

PDS to collaborate with MIT program

Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin. Brookfield-based Paragon Development Systems is partnering ...
Seeking Alpha

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted ...